A 24-year-old SMA patient in Kerala High Court revealed that Risdiplam, a crucial SMA drug, could be locally produced for Rs 3,000 annually compared to the current Rs 72 lakh. Highlighting the need for local manufacturing, the petition challenges the sufficiency of the Indian Health Ministry's financial aid and crowdfunding efforts. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
